14 research outputs found
Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenecity of human platelets
Tissue factor (TF) is an essential cofactor for the activation of blood coagulation in vivo. We now report that quiescent human platelets express TF pre-mRNA and, in response to activation, splice this intronic-rich message into mature mRNA. Splicing of TF pre-mRNA is associated with increased TF protein expression, procoagulant activity, and accelerated formation of clots. Pre-mRNA splicing is controlled by Cdc2-like kinase (Clk)1, and interruption of Clk1 signaling prevents TF from accumulating in activated platelets. Elevated intravascular TF has been reported in a variety of prothrombotic diseases, but there is debate as to whether anucleate platelets—the key cellular effector of thrombosis—express TF. Our studies demonstrate that human platelets use Clk1-dependent splicing pathways to generate TF protein in response to cellular activation. We propose that platelet-derived TF contributes to the propagation and stabilization of a thrombus
mTOR-dependent synthesis of Bcl-3 controls the retraction of fibrin clots by activated human platelets
Synthesis and Biological Evaluation of Pyrazolo[1,5‑<i>a</i>]pyrimidine Compounds as Potent and Selective Pim‑1 Inhibitors
Pim-1
has emerged as an attractive target for developing therapeutic
agents for treating disorders involving abnormal cell growth, especially
cancers. Herein we present lead optimization, chemical synthesis and
biological evaluation of pyrazolo[1,5-<i>a</i>]pyrimidine
compounds as potent and selective inhibitors of Pim-1 starting from
a hit from virtual screening. These pyrazolo[1,5-<i>a</i>]pyrimidine compounds strongly inhibited Pim-1 and Flt-3 kinases.
Selected compounds suppressed both the phosphorylation of BAD protein
in a cell-based assay and 2-dimensional colony formation in a clonogenic
cell survival assay at submicromolar potency, suggesting that cellular activity was mediated through
inhibition of Pim-1. Moreover, these Pim-1 inhibitors did not show
significant <i>h</i>ERG inhibition at 30 μM concentration.
The lead compound proved to be highly selective against a panel of
119 oncogenic kinases, indicating it had an improved safety profile
compared with the first generation Pim-1 inhibitor SGI-1776
Axl-RTK Inhibition Modulates T Cell Functions and Synergizes with Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies
A Small-Molecule Inhibitor of PIM Kinases as a Potential Treatment for Urothelial Carcinomas
The proto-oncogene proviral integration site for moloney murine leukemia virus (PIM) kinases (PIM-1, PIM-2, and PIM-3) are serine/threonine kinases that are involved in a number of signaling pathways important to cancer cells. PIM kinases act in downstream effector functions as inhibitors of apoptosis and as positive regulators of G1-S phase progression through the cell cycle. PIM kinases are upregulated in multiple cancer indications, including lymphoma, leukemia, multiple myeloma, and prostate, gastric, and head and neck cancers. Overexpression of one or more PIM family members in patient tumors frequently correlates with poor prognosis. The aim of this investigation was to evaluate PIM expression in low- and high-grade urothelial carcinoma and to assess the role PIM function in disease progression and their potential to serve as molecular targets for therapy. One hundred thirty-seven cases of urothelial carcinoma were included in this study of surgical biopsy and resection specimens. High levels of expression of all three PIM family members were observed in both noninvasive and invasive urothelial carcinomas. The second-generation PIM inhibitor, TP-3654, displays submicromolar activity in pharmacodynamic biomarker modulation, cell proliferation studies, and colony formation assays using the UM-UC-3 bladder cancer cell line. TP-3654 displays favorable human ether-à-go-go-related gene and cytochrome P450 inhibition profiles compared with the first-generation PIM inhibitor, SGI-1776, and exhibits oral bioavailability. In vivo xenograft studies using a bladder cancer cell line show that PIM kinase inhibition can reduce tumor growth, suggesting that PIM kinase inhibitors may be active in human urothelial carcinomas